Raphael Pharmaceutical Inc (RAPH)

[eye_ater]

On April 20, 2008, we entered into an exclusive purchasing and marketing
agreement ("Agreement") with Al-Sadeef Trading Company (headquartered in Jordan)
and its shareholders Mr. Tahseen Jasim Hamadi and Mr. Ali Jasim Hamadi
(collectively: the "Buyer") for the purchase, sale and marketing of our Yogen
product in the Middle East. Pursuant to the terms of the agreement, the Buyer
agreed to purchase a minimum of 300,000 units of the Yogen product per year for
a price per unit equal to the manufacturing price plus 30%, including all
shipment expenses incurred by us. The Agreement is filed as exhibit 10.1 to this
Quarterly Report on Form 10-Q and is incorporated herein by reference. We expect
to receive the first order in the coming days and under the Agreement we will be
obligated to use reasonable efforts to manufacture and ship the products within
90 days from acceptance of such order.